MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

By K. Savage, N. Johnson, S. Ben-Neriah, J. Connors, L. Sehn, Pedro Farinha, D. Horsman, R. Gascoyne. Blood, 2009

659 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. (2014, background): “For example, CNS involvement carries a poor prognosis and has been associated with MYC translocations, itself a marker of high-risk disease.(28) Limitations of the current study are principally those typically associated with observational studies using large health care databases.”
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “However, the prognostic significance of these rearrangements remains controversial and optimal clinical management is not established [14–16].”
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012, methodology): “FISH Translocations involving BCL2 and MYC were identified by interphase FISH in FFPE tissue in tissue microarrays from both data sets using commercial dual-color break-apart probes from Abbott Molecular (Abbott Park, IL) according to previously described methods.(14) Patient cases with break-apart ”